Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Clinical and Molecular Hepatology ; : 499-502, 2016.
Article in English | WPRIM | ID: wpr-54507

ABSTRACT

Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban.


Subject(s)
Female , Humans , Middle Aged , Administration, Oral , Factor Xa Inhibitors/therapeutic use , Liver Cirrhosis/complications , Portal Vein , Recurrence , Rivaroxaban/therapeutic use , Tomography, X-Ray Computed , Venous Thrombosis/complications
SELECTION OF CITATIONS
SEARCH DETAIL